#USA #AI Solutions #Persistent Systems #Pune #NVIDIA

Introduction to Persistence's Innovations

Persistent Systems, a leader in digital engineering, is set to transform the landscape of drug discovery through their new Artificial Intelligence solutions. Partnering with NVIDIA, the company has developed innovative tools aimed at the healthcare and life sciences sectors. These advancements promise to streamline processes, ensure compliance, and enhance the speed of research outcomes.

Partnership with NVIDIA

On March 17, 2026, Persistent Systems revealed a collaboration with NVIDIA, known for their robust AI frameworks. This partnership is focused on harnessing AI to facilitate drug discovery and enhance research capabilities within Health and Life Sciences (HLS) organizations, which are often faced with complex regulatory demands and data-intensive operational environments.

By integrating Persistent's specialized knowledge with NVIDIA's AI platform, healthcare organizations can transition from experimental AI applications to practical implementations in critical environments. This collaboration aims to realize faster therapeutic discoveries amid increasing global healthcare demands.

Generative Molecules and Virtual Screening

One of the groundbreaking initiatives from Persistent is the Generative Molecules and Virtual Screening (GenMoIVS) solution. This innovative tool utilizes the NVIDIA BioNeMo framework, allowing for sophisticated molecular simulations and virtual screenings. Through high-fidelity modeling of biological and chemical behaviors, GenMoIVS enables HLS organizations to conduct effective preclinical research.

The GenMoIVS solution enhances the drug discovery workflow by fostering intelligent agents capable of real-time decision-making. This allows research teams to prioritize candidates and streamline their experimental planning, ultimately translating digital simulations into actionable insights for clinical laboratories.

The Impact of AI on Drug Discovery

Persistent's efforts focus on easing the burden of traditional research and development, which often involves long lead times and extensive labor. By employing AI-driven molecular modeling, the company aims to reduce this timeline substantially, from months to mere days, without compromising scientific integrity or regulatory compliance.

The simulation-centric approach not only accelerates the research cycle but also increases the likelihood of success in clinical development pipelines by mitigating risks during early-stage discovery processes.

Advanced Technological Applications

In addition to creating GenMoIVS, Persistent is looking to further enhance this offering by integrating NVIDIA Nemotron open models within the solution. These models facilitate the generation of highly accurate AI outputs that will be ingrained in enterprise workflows, thereby optimizing operational efficiency.

To scale the production of reliable applications, Persistent plans to leverage NVIDIA's accelerated computing resources, servers, and its comprehensive AI enterprise systems. This infrastructure will support advanced simulation and inference capabilities, ensuring efficient real-time data analysis even in stringent research environments.

Enhancing AI and Engineering Capabilities

Through this collaboration, Persistent is also set to bolster its engineering capabilities within the AI space. By utilizing NVIDIA's AI training resources and certification programs, the company seeks to equip its personnel with state-of-the-art skills necessary to construct sophisticated data platforms for enhanced client services.

Comments from Leadership

Ganesh Nathella, Executive Vice President at Persistent, emphasized, "Healthcare and Life Sciences organizations must accelerate their therapy discovery processes. Traditional RD can be labor-intensive and slow, and our collaboration with NVIDIA leverages Generative AI to fulfill this gap. Our GenMoIVS technology helps BioPharma companies transition from extensive experiments to swift AI-assisted discoveries."

In alignment with this sentiment, John Fanelli, NVIDIA's Vice President, acknowledged the urgency in the healthcare sector for innovative therapy development. By utilizing NVIDIA's AI architecture, Persistent is equipping biopharma entities with advanced systems for molecular simulations and virtual screenings.

Conclusion

Persistent Systems' innovative AI-powered solutions represent a significant leap forward for the healthcare and life sciences sectors. As the demand for novel therapeutics increases globally, these technologies are primed to enhance the speed and efficiency of drug discovery processes. With well-structured plans for scalability and enhancement, Persistent and NVIDIA are positioned to play pivotal roles in the future of healthcare innovation.